Relaxin, a pleiotropic vasodilator for the treatment of heart failure

被引：0
作者：
Sam L. Teichman
Elaine Unemori
Thomas Dschietzig
Kirk Conrad
Adriaan A. Voors
John R. Teerlink
G. Michael Felker
Marco Metra
Gad Cotter
机构：
[1] Corthera Inc.,Department of Cardiology and Angiology
[2] Charité Hospital – University Medicine,Department of Physiology and Functional Genomics
[3] University of Florida College of Medicine,Department of Cardiology, Thoraxcenter
[4] University Medical Center Groningen,Section of Cardiology, Veterans Affairs Medical Center
[5] University of California,Department of Cardiology
[6] Duke Clinical Research Institute,Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine
[7] University of Brescia,undefined
[8] Momentum Research Inc.,undefined
来源：
Heart Failure Reviews | 2009年 / 14卷
关键词：
Relaxin; Acute heart failure; Vasodilator; Hemodynamic; Renovascular;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Relaxin is a naturally occurring peptide hormone that plays a central role in the hemodynamic and renovascular adaptive changes that occur during pregnancy. Triggering similar changes could potentially be beneficial in the treatment of patients with heart failure. The effects of relaxin include the production of nitric oxide, inhibition of endothelin, inhibition of angiotensin II, production of VEGF, and production of matrix metalloproteinases. These effects lead to systemic and renal vasodilation, increased arterial compliance, and other vascular changes. The recognition of this has led to the study of relaxin for the treatment of heart failure. An initial pilot study has shown favorable hemodynamic effects in patients with heart failure, including reduction in ventricular filling pressures and increased cardiac output. The ongoing RELAX-AHF clinical program is designed to evaluate the effects of relaxin on the symptoms and outcomes in a large group of patients admitted to hospital for acute heart failure. This review will summarize both the biology of relaxin and the data supporting its potential efficacy in human heart failure.
引用
收藏
页码：321 / 329
页数：8
相关论文
共 118 条
  • [31] Debrah DO(2005)Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8) J Pharmacol Exp Ther 313 677-687
  • [32] Conrad KP(2006)Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP Signaling by distinct mechanisms Mol Pharmacol 70 214-226
  • [33] Debrah DO(2007)Comparison of signaling pathways activated by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes J Pharmacol Exp Ther 320 281-290
  • [34] Conrad KP(2005)The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway Kidney Int 68 96-109
  • [35] Dries D(1967)Effects of relaxin on the endothelium of endometrial blood vessels in monkeys ( Endocrinology 81 375-385
  • [36] Exner D(2002)) Science 295 671-674
  • [37] Domanski M(2007)Activation of orphan receptors by the hormone relaxin Front Biosci 12 2425-2437
  • [38] Greenberg B(2003)Renal function during normal pregnancy and preeclampsia Circ Res 93 1249-1257
  • [39] Stevenson L(2007)Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small renal arteries Adv Exp Med Biol 612 65-87
  • [40] Dschietzig T(1998)The vascular actions of relaxin Biol Reprod 59 991-999
12345678910